Dr. Akinlolu Ojo

Executive Dean & Professor of Medicine and Population Health

University of Kansas School of Medicine

In person and via Zoom

Upon completion of this activity, participants will be able to:

• Describe the epidemiology of end stage renal disease in African Americans and other Black populations
• Explain how apolipoprotein L1 (APOL1) kidney risk variants mediate kidney injury
• Identify which patients and family members should undergo APOL1 genetic screening tests
• List the emerging therapeutic options for APOL1-mediated kidney disease
   

Disclosure of Financial Interest Summary

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

The planners, faculty, and others in control of educational content for this educational activity have relevant financial relationship(s) to disclose: none

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include a discussion of investigational agents and/or off- label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off label uses.

Disclosure of relationships is not intended to suggest or condone commercial bias in any presentations, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation